Target intelligence / Profile preview

NALCN channel auxiliary factor 1 (NALF1)

Target
NALF1
Molecular classification
Ion channel auxiliary subunit, Other (Transmembrane protein; Channel auxiliary factor)
01

Overview

NALCN channel auxiliary factor 1 (NALF1), also known as FAM155A, is a transmembrane protein that functions as an essential auxiliary component of the NALCN sodium leak channel complex[1][3][6]. It facilitates proper folding, assembly, and membrane localization of the NALCN channel, which is responsible for the basal sodium permeability of neurons and plays a critical role in maintaining resting membrane potential and regulating excitability in the central nervous system[2][3][6]. NALF1 is predicted to contribute to stretch-activated, cation-selective channel activity and is involved in calcium ion import across the plasma membrane[1][3]. Mutations or dysfunction in the NALCN complex, including its auxiliary factors such as NALF1, have been implicated in severe neurodevelopmental syndromes, although NALF1 itself is not currently an established therapeutic target and no drugs are known to act on it directly[3][2][6].

Other names
NAF1FAM155AFamily with sequence similarity 155 member ANLF-1NALCN channel auxiliary factor 1Transmembrane protein FAM155ANLF1
02

Mechanism of action

No known small-molecule mechanisms directly targeting NALF1. Essential for correct localization and assembly of the NALCN channel complex, which can be modulated by proteins/factors affecting NALCN function[2][3][6].

03

Biological functions

Regulation of sodium leak channel (NALCN) functionModulation of neuronal excitabilityProtein trafficking and membrane localization of the NALCN complexFacilitates calcium ion import across plasma membranePutative role as chaperone for channel assembly
04

Disease associations

Neurodevelopmental disorders (e.g., motor and cognitive impairment associated with NALCN dysfunction)Pancreatic cancerOther disorders involving altered neuronal excitability
05

Safety considerations

No direct therapeutic exploitation or associated pharmacovigilance known for NALF1 alone.Disruption may contribute to altered neuronal excitability, leading to hypotonia, speech, and cognitive delay (in the context of NALCN complex dysregulation)[2][3].
06

Interacting drugs

None established; no approved or clinically recognized drugs directly target NALF1 as a primary pharmacological target.

1 more in the full profile.

07

Biomarkers

None established for clinical use specific to NALF1.

Beyond the preview

Go deeper on NALCN channel auxiliary factor 1 (NALF1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on NALCN channel auxiliary factor 1 (NALF1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call